Molecular remodeling in comorbidities associated with heart failure: a current update.
Atrial fibrillation
Chronic kidney disease
Coronary artery disease
Diabetes mellitus
Heart failure
Hypercholesteremia
Obesity
Pulmonary hypertension
Systemic hypertension
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
19
05
2024
accepted:
14
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
26
10
2024
Statut:
epublish
Résumé
Recent advances in genomics and proteomics have helped in understanding the molecular mechanisms and pathways of comorbidities and heart failure. In this narrative review, we reviewed molecular alterations in common comorbidities associated with heart failure such as obesity, diabetes mellitus, systemic hypertension, pulmonary hypertension, coronary artery disease, hypercholesteremia and lipoprotein abnormalities, chronic kidney disease, and atrial fibrillation. We searched the electronic databases, PubMed, Ovid, EMBASE, Google Scholar, CINAHL, and PhysioNet for articles without time restriction. Although the association between comorbidities and heart failure is already well established, recent studies have explored the molecular pathways in much detail. These molecular pathways demonstrate how novels drugs for heart failure works with respect to the pathways associated with comorbidities. Understanding the altered molecular milieu in heart failure and associated comorbidities could help to develop newer medications and targeted therapies that incorporate these molecular alterations as well as key molecular variations across individuals to improve therapeutic outcomes. The molecular alterations described in this study could be targeted for novel and personalized therapeutic approaches in the future. This knowledge is also critical for developing precision medicine strategies to improve the outcomes for patients living with these conditions.
Identifiants
pubmed: 39460797
doi: 10.1007/s11033-024-10024-7
pii: 10.1007/s11033-024-10024-7
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1092Informations de copyright
© 2024. The Author(s).
Références
Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N et al (2021) Universal definition and classification of heart failure: a report of the heart failure society of America, heart failure association of the European society of cardiology, Japanese heart failure society and writing committee of the universal definition of heart failure. J Card Fail 27(4):387–413
doi: 10.1016/j.cardfail.2021.01.022
Doran S, Arif M, Lam S, Bayraktar A, Turkez H, Uhlen M et al (2021) Multi-omics approaches for revealing the complexity of cardiovascular disease. Brief Bioinform 22(5):bbab061
pubmed: 33725119
pmcid: 8425417
doi: 10.1093/bib/bbab061
Tham YK, Bernardo BC, Ooi JY, Weeks KL, McMullen JR (2015) Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch Toxicol 89:1401–1438
pubmed: 25708889
doi: 10.1007/s00204-015-1477-x
Zhang Y, Ren J (2016) Epigenetics and obesity cardiomyopathy: from pathophysiology to prevention and management. Pharmacol Ther 161:52–66
pubmed: 27013344
doi: 10.1016/j.pharmthera.2016.03.005
Tsigkou V, Oikonomou E, Anastasiou A, Lampsas S, Zakynthinos GE, Kalogeras K et al (2023) Molecular mechanisms and therapeutic implications of endothelial dysfunction in patients with heart failure. Int J Mol Sci 24(5):4321
pubmed: 36901752
pmcid: 10001590
doi: 10.3390/ijms24054321
Screever EM, van der Wal MH, van Veldhuisen DJ, Jaarsma T, Koops A, van Dijk KS et al (2023) Comorbidities complicating heart failure: changes over the last 15 years. Clin Res Cardiol 112(1):123–133
Kokkinos P, Faselis C, Franklin B, Lavie CJ, Sidossis L, Moore H et al (2019) Cardiorespiratory fitness, body mass index and heart failure incidence. Eur J Heart Fail 21(4):436–444
pubmed: 30779281
doi: 10.1002/ejhf.1433
Benn M, Marott SC, Tybjærg-Hansen A, Nordestgaard BG (2023) Obesity increases heart failure incidence and mortality: observational and mendelian randomization studies totalling over 1 million individuals. Cardiovascular Res 118(18):3576–3585
Shen Q, Hiebert JB, Rahman FK, Krueger KJ, Gupta B, Pierce JD (2021) Understanding obesity-related high output heart failure and its implications. Int J Heart Fail 3(3):160–171
pubmed: 36262639
pmcid: 9536652
doi: 10.36628/ijhf.2020.0047
Lopaschuk GD, Karwi QG, Tian R, Wende AR, Abel ED (2021) Cardiac energy metabolism in heart failure. Circul Res 128(10):1487–1513
doi: 10.1161/CIRCRESAHA.121.318241
Satoh T, Wang L, Espinosa-Diez C, Wang B, Hahn SA, Noda K et al (2021) Metabolic syndrome mediates ROS-miR-193b-NFYA–Dependent downregulation of Soluble Guanylate Cyclase and contributes to Exercise-Induced Pulmonary Hypertension in Heart failure with preserved ejection fraction. Circulation 144(8):615–637
pubmed: 34157861
pmcid: 8384699
doi: 10.1161/CIRCULATIONAHA.121.053889
Schiattarella GG, Altamirano F, Kim SY, Tong D, Ferdous A, Piristine H et al (2021) Xbp1s-FoxO1 axis governs lipid accumulation and contractile performance in heart failure with preserved ejection fraction. Nat Commun 12(1):1–14
doi: 10.1038/s41467-021-21931-9
Wang X, Xu Z, Chang R, Zeng C, Zhao Y (2023) High-fructose Diet induces Cardiac Dysfunction via Macrophage Recruitment in Adult mice. J Cardiovasc Pharmacol Therap 28:10742484231162249
doi: 10.1177/10742484231162249
Almengló C, Fu X, Flores-Arias MT, Fernández ÁL, Viñuela JE, Martínez‐Cereijo JM et al (2022) Synergism between obesity and HFpEF on neutrophils phenotype and its regulation by adipose tissue‐molecules and SGLT2i dapagliflozin. J Cell Mol Med 26(16):4416–4427
pubmed: 35818731
pmcid: 9357605
doi: 10.1111/jcmm.17466
Lin K, Yang N, Luo W, Qian J-f, Zhu W-w, Ye S-j et al (2022) Direct cardio-protection of Dapagliflozin against obesity-related cardiomyopathy via NHE1/MAPK signaling. Acta Pharmacol Sin 43(10):2624–2635
pubmed: 35217813
pmcid: 9525284
doi: 10.1038/s41401-022-00885-8
Jha KK, Adhikari R, Tasdighi E, Osuji N, Rajan T, Blaha MJ (2022) Transitioning to GLP-1 RAs and SGLT2 inhibitors as the first choice for managing cardiometabolic risk in type 2 diabetes. Curr Atheroscler Rep 24(12):925–937
Adamson C, Kondo T, Jhund PS, de Boer RA, Cabrera Honorio JW, Claggett B et al (2022) Dapagliflozin for heart failure according to body mass index: the DELIVER trial. Eur Heart J 43(41):4406–4417
pubmed: 36029309
pmcid: 9622300
doi: 10.1093/eurheartj/ehac481
Oyama K, Raz I, Cahn A, Kuder J, Murphy SA, Bhatt DL et al (2022) Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial. Eur Heart J 43(31):2958–2967
pubmed: 34427295
doi: 10.1093/eurheartj/ehab530
Xie B, Ramirez W, Mills AM, Huckestein BR, Anderson M, Pangburn MM et al (2022) Empagliflozin restores cardiac metabolic flexibility in diet-induced obese C57BL6/J mice. Curr Res Physiol 5:232–239
pubmed: 35677213
pmcid: 9168377
doi: 10.1016/j.crphys.2022.05.003
Takasu T, Takakura S (2019) Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy. Life Sci 230:19–27
pubmed: 31125563
doi: 10.1016/j.lfs.2019.05.051
Mordi IR, Lumbers RT, Palmer CN, Pearson ER, Sattar N, Holmes MV et al (2021) Type 2 diabetes, metabolic traits, and risk of Heart failure: a mendelian randomization study. Diabetes Care 44(7):1699–1705
pubmed: 34088700
pmcid: 8323186
doi: 10.2337/dc20-2518
Maffei A, Lembo G, Carnevale D (2018) PI3Kinases in diabetes mellitus and its related complications. Int J Mol Sci 19(12):4098
pubmed: 30567315
pmcid: 6321267
doi: 10.3390/ijms19124098
Han Z, Zhao D, Han M, Zhang R, Hao Y (2022) Knockdown of miR-372-3p Inhibits the Development of Diabetic Cardiomyopathy by Accelerating Angiogenesis via Activating the PI3K/AKT/mTOR/HIF-1α Signaling Pathway and Suppressing Oxidative Stress. Oxidative Medicine and Cellular Longevity. 2022
Wu X, Liu H, Brooks A, Xu S, Luo J, Steiner R et al (2022) SIRT6 mitigates heart failure with preserved ejection fraction in diabetes. Circul Res 131(11):926–943
doi: 10.1161/CIRCRESAHA.121.318988
Khan D, Ara T, Ravi V, Rajagopal R, Tandon H, Parvathy J et al (2021) SIRT6 transcriptionally regulates fatty acid transport by suppressing PPARγ. Cell Rep 35(9):109190
pubmed: 34077730
pmcid: 8190874
doi: 10.1016/j.celrep.2021.109190
Li H, Fan J, Zhao Y, Zhang X, Dai B, Zhan J et al (2019) Nuclear miR-320 mediates diabetes-induced cardiac dysfunction by activating transcription of fatty acid metabolic genes to cause lipotoxicity in the heart. Circul Res 125(12):1106–1120
doi: 10.1161/CIRCRESAHA.119.314898
Veitch S, Njock M-S, Chandy M, Siraj MA, Chi L, Mak H et al (2022) MiR-30 promotes fatty acid beta-oxidation and endothelial cell dysfunction and is a circulating biomarker of coronary microvascular dysfunction in pre-clinical models of diabetes. Cardiovasc Diabetol 21(1):1–18
doi: 10.1186/s12933-022-01458-z
Mu J, Zhang D, Tian Y, Xie Z, Zou M-h (2020) BRD4 inhibition by JQ1 prevents high-fat diet-induced diabetic cardiomyopathy by activating PINK1/Parkin-mediated mitophagy in vivo. J Mol Cell Cardiol 149:1–14
pubmed: 32941882
pmcid: 7736123
doi: 10.1016/j.yjmcc.2020.09.003
Wang Z, Gu Y, Sun Y, Xu Y, Zhang M, Jiang T (2021) Analysis of communal molecular mechanism and potential therapeutic targets in heart failure and type 2 diabetes Mellitus. Int J Gen Med 14:6549
pubmed: 34675622
pmcid: 8518481
doi: 10.2147/IJGM.S325339
Guo Q, Zhu Q, Zhang T, Qu Q, Cheang I, Liao S et al (2022) Integrated bioinformatic analysis reveals immune molecular markers and potential drugs for diabetic cardiomyopathy. Front Endocrinol (Lausanne) 15(13):933635
Xu H, Qin J, Qin X, Guo C, Yang B (2022) Bioinformatics and in silico findings uncover bio-targets of calycosin against heart failure and diabetes mellitus. Front Endocrinol (Lausanne) 8(13):790619
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Bělohlávek J et al (2020) Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. JAMA 323(14):1353–1368
pubmed: 32219386
pmcid: 7157181
doi: 10.1001/jama.2020.1906
Khan MS, Felker GM, Piña IL, Camacho A, Bapat D, Ibrahim NE et al (2021) Reverse cardiac remodeling following initiation of sacubitril/valsartan in patients with heart failure with and without diabetes. Heart Fail 9(2):137–145
Wijkman MO, Claggett B, Vaduganathan M, Cunningham JW, Rørth R, Jackson A et al (2022) Effects of sacubitril/valsartan on glycemia in patients with diabetes and heart failure: the PARAGON-HF and PARADIGM-HF trials. Cardiovasc Diabetol 21(1):110
pubmed: 35717169
pmcid: 9206286
doi: 10.1186/s12933-022-01545-1
Shou J, Huo Y (2022) PINK1 phosphorylates Drp1S616 to improve mitochondrial fission and inhibit the Progression of Hypertension-Induced HFpEF. Int J Mol Sci 23(19):11934
pubmed: 36233236
pmcid: 9570161
doi: 10.3390/ijms231911934
Bednarski TK, Duda MK, Dobrzyn P (2022) Alterations of lipid metabolism in the heart in spontaneously hypertensive rats precedes left ventricular hypertrophy and Cardiac Dysfunction. Cells 11(19):3032
pubmed: 36230994
pmcid: 9563594
doi: 10.3390/cells11193032
Ashur C, Frishman WH (2018) Cardiosphere-Derived cells and ischemic heart failure. Cardiol Rev 26(1):8–21
pubmed: 29206745
doi: 10.1097/CRD.0000000000000173
Couto Gd, Mesquita T, Wu X, Rajewski A, Huang F, Akhmerov A et al (2022) Cell therapy attenuates endothelial dysfunction in hypertensive rats with heart failure and preserved ejection fraction. Am J Physiol Heart Circ Physiol 323(5):H892–H903
pubmed: 36083797
doi: 10.1152/ajpheart.00287.2022
Zhang R, Xu X, Chen X, Hao C, Ji Z, Zuo P et al (2022) Upregulation of key genes Eln and Tgfb3 were associated with the severity of cardiac hypertrophy. BMC Genomics 23(1):592
pubmed: 35964009
pmcid: 9375926
doi: 10.1186/s12864-022-08778-0
Mithieux SM, Weiss AS (2005) Elastin. Advances in protein chemistry. 70:437 – 61
Ren H, Luo J-Q, Ouyang F, Cheng L, Chen X-P, Zhou H-H et al (2021) WNT3A rs752107(C > T) polymorphism is Associated with an increased risk of essential hypertension and related Cardiovascular diseases. Front Cardiovasc Med. 8
MacDonnell S, Megna J, Ruan Q, Zhu O, Halasz G, Jasewicz D et al (2022) Activin A directly impairs human cardiomyocyte contractile function indicating a potential role in heart failure development. Front Cardiovasc Med. 9
Mondaca-Ruff D, Araos P, Yañez CE, Novoa UF, Mora IG, Ocaranza MP et al (2021) Hydrochlorothiazide reduces cardiac hypertrophy, fibrosis and rho-kinase activation in DOCA-Salt Induced Hypertension. J Cardiovasc Pharmacol Therap 26(6):724–735
doi: 10.1177/10742484211053109
Ruopp NF, Cockrill BA (2022) Diagnosis and treatment of pulmonary arterial hypertension: a review. JAMA 327(14):1379–1391
pubmed: 35412560
doi: 10.1001/jama.2022.4402
Morrell NW, Aldred MA, Chung WK, Elliott CG, Nichols WC, Soubrier F et al (2019) Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 53(1)
Pattathu J, Gorenflo M, Hilgendorff A, Koskenvuo JW, Apitz C, Hansmann G et al (2016) Genetic testing and blood biomarkers in paediatric pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLT and DGPK. Heart 102(Suppl 2):ii36–ii41
pubmed: 27053696
doi: 10.1136/heartjnl-2014-307238
Du M, Jiang H, Liu H, Zhao X, Zhou Y, Zhou F et al (2022) Single-cell RNA sequencing reveals that BMPR2 mutation regulates right ventricular function via ID genes. Eur Respir J. 60(1)
Park A-M, Wong C-M, Jelinkova L, Liu L, Nagase H, Suzuki YJ (2010) Pulmonary hypertension-induced GATA4 activation in the right ventricle. Hypertension 56(6):1145–1151
pubmed: 21059997
doi: 10.1161/HYPERTENSIONAHA.110.160515
Houssaini A, Abid S, Mouraret N, Wan F, Rideau D, Saker M et al (2013) Rapamycin reverses pulmonary artery smooth muscle cell proliferation in pulmonary hypertension. Am J Respir Cell Mol Biol 48(5):568–577
pubmed: 23470622
doi: 10.1165/rcmb.2012-0429OC
McNair BD, Schlatter JA, Cook RF, Yusifova M, Bruns DR (2021) Inhibition of mTOR by rapamycin does not improve hypoxic pulmonary hypertension-induced right heart failure in old mice. Exp Gerontol 151:111395
pubmed: 33971279
pmcid: 8248895
doi: 10.1016/j.exger.2021.111395
Cao Y, Yang Y, Wang L, Li L, Zhang J, Gao X et al (2018) Analyses of long non-coding RNA and mRNA profiles in right ventricle myocardium of acute right heart failure in pulmonary arterial hypertension rats. Biomed Pharmacother 106:1108–1115
pubmed: 30119177
doi: 10.1016/j.biopha.2018.07.057
Legchenko E, Chouvarine P, Borchert P, Fernandez-Gonzalez A, Snay E, Meier M et al (2018) PPARγ agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation. Sci Transl Med 10(438):eaao0303
pubmed: 29695452
doi: 10.1126/scitranslmed.aao0303
Frump AL, Albrecht M, Yakubov B, Breuils-Bonnet S, Nadeau V, Tremblay E et al (2021) 17β-Estradiol and estrogen receptor α protect right ventricular function in pulmonary hypertension via BMPR2 and apelin. J Clin Investig. 131(6)
Falcone C, Bozzini S, Matrone B, Colonna A, Falcone R, Calcagnino M et al (2013) RAGE gene polymorphism in heart failure patients with and without angiographic evidence of significant coronary atherosclerosis. Int J ImmunoPathol Pharmacol 26(1):199–206
pubmed: 23527722
doi: 10.1177/039463201302600119
Kravchun P, Kadykova O, Ryndina N, Krapivko S, Kozhyn M, Zolotaikina V (2020) Relationship between interleukin-6 gene polymorphism and heart failure in patients with coronary artery disease and obesity. Wiad Lek 73(8):1637–1640
Katzmann JL, Mason AM, März W, Kleber ME, Niessner A, Blüher M et al (2021) Genetic variation in sodium-glucose cotransporter 2 and heart failure. Clin Pharmacol Ther 110(1):149–158
pubmed: 33405238
doi: 10.1002/cpt.2153
Jin J, Zhu C, Wang J, Zhao X, Yang R (2022) The association between ACTB methylation in peripheral blood and coronary heart disease in a case-control study. Front Cardiovasc Med. 9
Nicholls SJ, Schwartz GG, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K et al (2021) Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc Diabetol 20(1):1–9
doi: 10.1186/s12933-020-01199-x
Wang A, Zhao W, Yan K, Guo L, Gao F, Chen J et al (2022) Investigating the cardioprotective effects of Fuzheng Yangxin recipe based on network pharmacology and experimental evaluation. Front Pharmacol. 13
Aboumsallem JP, Muthuramu I, Mishra M, De Geest B (2019) Cholesterol-lowering gene therapy prevents heart failure with preserved ejection fraction in obese type 2 diabetic mice. Int J Mol Sci 20(9):2222
pubmed: 31064116
pmcid: 6539537
doi: 10.3390/ijms20092222
Muthuramu I, Mishra M, Aboumsallem JP, Postnov A, Gheysens O, De Geest B (2019) Cholesterol lowering attenuates pressure overload-induced heart failure in mice with mild hypercholesterolemia. Aging 11(17):6872
pubmed: 31484164
pmcid: 6756886
doi: 10.18632/aging.102218
Kronenberg F (2022) Lipoprotein (a). Handb Exp Pharmacol 270:201–232
pubmed: 34196811
doi: 10.1007/164_2021_504
White HD, Schwartz GG, Szarek M, Bhatt DL, Bittner VA, Chiang C-E et al (2022) Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J 43(16):1554–1565
pubmed: 34922353
doi: 10.1093/eurheartj/ehab804
Lagace TA (2014) PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells. Curr Opin Lipidol 25(5):387
pubmed: 25110901
pmcid: 4166010
doi: 10.1097/MOL.0000000000000114
Bouwens E, Schuurman A-S, Akkerhuis KM, Manintveld OC, Caliskan K, van Ramshorst J et al (2021) Associations of serially measured PCSK9, LDLR and MPO with clinical outcomes in heart failure. Biomark Med 15(4):247–255
pubmed: 33590771
doi: 10.2217/bmm-2020-0585
Bayes-Genis A, Núñez J, Zannad F, Ferreira JP, Anker SD, Cleland JG et al (2017) The PCSK9-LDL receptor axis and outcomes in heart failure: BIOSTAT-CHF subanalysis. J Am Coll Cardiol 70(17):2128–2136
pubmed: 29050560
doi: 10.1016/j.jacc.2017.08.057
Laudette M, Lindbom M, Arif M, Cinato M, Ruiz M, Doran S et al (2023) Cardiomyocyte-specific PCSK9 deficiency compromises mitochondrial bioenergetics and heart function. Cardiovasc Res 119(7):1537–1552
Da Dalt L, Castiglioni L, Baragetti A, Audano M, Svecla M, Bonacina F et al (2021) PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction. Eur Heart J 42(32):3078–3090
pubmed: 34252181
pmcid: 8380058
doi: 10.1093/eurheartj/ehab431
Trudsø LC, Ghouse J, Ahlberg G, Bundgaard H, Olesen MS (2023) Association of PCSK9 loss-of-function variants with risk of heart failure. JAMA Cardiol 8(2):159–166
pubmed: 36542369
doi: 10.1001/jamacardio.2022.4798
Xiao J, Ji J, Yang X, Chen K, Chen L, Huang W (2022) Association of genetically-predicted lipid traits and lipid-modifying targets with the risk of heart failure. Eur J Prev Cardiol 30(4):358–366
Eirin A, Chade AR (2023) Cardiac epigenetic changes in VEGF signaling genes associate with myocardial microvascular rarefaction in experimental chronic kidney disease. Am J Physiol Heart Circ Physiol 324(1):H14–H25
pubmed: 36367693
doi: 10.1152/ajpheart.00522.2022
Chade AR, Eirin A (2022) Cardiac micro-RNA and transcriptomic profile of a novel swine model of chronic kidney disease and left ventricular diastolic dysfunction. Am J Physiol Heart Circ Physiol 323(4):H659–H69
pubmed: 36018756
pmcid: 9512116
doi: 10.1152/ajpheart.00333.2022
Ahmed MM, Ishrat R, Tazyeen S, Alam A, Farooqui A, Ali R et al (2021) In silico integrative approach revealed key microRNAs and associated target genes in cardiorenal syndrome. Bioinform Biol Insights 15:11779322211027396
pubmed: 34276211
pmcid: 8256246
doi: 10.1177/11779322211027396
Nicolas D, Kerndt CC, Reed M (2018) Sacubitril/valsartan
Haynes R, Zhu D, Judge PK, Herrington WG, Kalra PA, Baigent C (2020) Chronic kidney disease, heart failure and neprilysin inhibition. Nephrol Dialysis Transplantation 35(4):558–564
doi: 10.1093/ndt/gfz058
Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A et al (2018) Effects of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: a randomized double-blind trial. Circulation 138(15):1505–1514
pubmed: 30002098
doi: 10.1161/CIRCULATIONAHA.118.034818
Liu LC, Schutte E, Gansevoort RT, van der Meer P, Voors AA (2015) Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. Expert Opin Investig Drugs 24(8):1123–1135
pubmed: 26095025
doi: 10.1517/13543784.2015.1059819
Filippatos G, Anker SD, Pitt B, Rossing P, Joseph A, Kolkhof P et al (2022) Finerenone and heart failure outcomes by kidney Function/Albuminuria in chronic kidney disease and diabetes. JACC: Heart Fail 10(11):860–870
pubmed: 36328655
Filippatos G, Anker SD, Böhm M, Gheorghiade M, Køber L, Krum H et al (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. Eur Heart J 37(27):2105–2114
pubmed: 27130705
pmcid: 4946749
doi: 10.1093/eurheartj/ehw132
Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L et al (2018) Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 378(5):417–427
pubmed: 29385358
doi: 10.1056/NEJMoa1707855
Arora R (2017) Gene therapy for atrial fibrillation in heart failure. Clin Pharmacol Ther 102(2):200–202
pubmed: 28548218
doi: 10.1002/cpt.717
Zeemering S, Isaacs A, Winters J, Maesen B, Bidar E, Dimopoulou C et al (2022) Atrial fibrillation in the presence and absence of heart failure enhances expression of genes involved in cardiomyocyte structure, conduction properties, fibrosis, inflammation, and endothelial dysfunction. Heart Rhythm 19(12):2115–2124
pubmed: 36007727
doi: 10.1016/j.hrthm.2022.08.019
Zhuang Y, Qiao Z, Bi X, Han D, Jiang Q, Zhang Y et al (2022) Screening and Bioinformatics Analysis of Crucial Gene of Heart failure and Atrial Fibrillation based on GEO Database. Medicina 58(10):1319
pubmed: 36295481
pmcid: 9608246
doi: 10.3390/medicina58101319
Amir O, Amir RE, Paz H, Mor R, Sagiv M, Lewis BS (2008) Aldosterone synthase gene polymorphism as a determinant of atrial fibrillation in patients with heart failure. Am J Cardiol 102(3):326–329
pubmed: 18638595
doi: 10.1016/j.amjcard.2008.03.063
Kitamura K, Shibata R, Tsuji Y, Shimano M, Inden Y, Murohara T (2011) Eicosapentaenoic acid prevents atrial fibrillation associated with heart failure in a rabbit model. Am J Physiol Heart Circ Physiol 300(5):H1814–H21
pubmed: 21335470
doi: 10.1152/ajpheart.00771.2010
Behnes M, Hoffmann U, Lang S, Weiss C, Ahmad-Nejad P, Neumaier M et al (2011) Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure. Clin Res Cardiol 100:335–342
pubmed: 21069358
doi: 10.1007/s00392-010-0248-1
Ma S, Yan F, Hou Y (2023) Intermedin 1–53 ameliorates Atrial Fibrosis and reduces inducibility of Atrial Fibrillation via TGF-β1/pSmad3 and Nox4 pathway in a rat model of heart failure. J Clin Med 12(4):1537
pubmed: 36836072
pmcid: 9959393
doi: 10.3390/jcm12041537
Dridi H, Kushnir A, Zalk R, Yuan Q, Melville Z, Marks AR (2020) Intracellular calcium leak in heart failure and atrial fibrillation: a unifying mechanism and therapeutic target. Nat Reviews Cardiol 17(11):732–747
doi: 10.1038/s41569-020-0394-8
Nofi C, Zhang K, Tang Y-D, Li Y, Migirov A, Ojamaa K et al (2020) Chronic dantrolene treatment attenuates cardiac dysfunction and reduces atrial fibrillation inducibility in a rat myocardial infarction heart failure model. Heart Rhythm O2 1(2):126–135
pubmed: 34113867
pmcid: 8183840
doi: 10.1016/j.hroo.2020.03.004
Liu Z, Finet JE, Wolfram JA, Anderson ME, Ai X, Donahue JK (2019) Calcium/calmodulin-dependent protein kinase II causes atrial structural remodeling associated with atrial fibrillation and heart failure. Heart Rhythm 16(7):1080–1088
pubmed: 30654134
pmcid: 6800146
doi: 10.1016/j.hrthm.2019.01.013
Femminella GD, Pagano G, Liccardo D, Cannavo A (2021) Molecular mechanisms involved in heart failure, Parkinson’s, and Alzheimer’s diseases. Frontiers Media SA, p 754987
Grosu L, Grosu AI, Crisan D, Zlibut A, Perju-Dumbrava L (2023) Parkinson’s disease and cardiovascular involvement: edifying insights. Biomedical Rep 18(3):1–8
doi: 10.3892/br.2023.1607
Perez-Lloret S, Rey MV, Crispo J, Krewski D, Lapeyre-Mestre M, Montastruc J-L et al (2014) Risk of heart failure following treatment with dopamine agonists in Parkinson’s disease patients. Exp Opin Drug Saf 13(3):351–360
doi: 10.1517/14740338.2014.888057
Tran T, Brophy JM, Suissa S, Renoux C (2015) Risks of cardiac valve regurgitation and heart failure associated with ergot-and non-ergot-derived dopamine agonist use in patients with Parkinson’s disease: a systematic review of observational studies. CNS Drugs 29:985–998
pubmed: 26585874
doi: 10.1007/s40263-015-0293-4
Kutikuppala LVS, Sharma S, Chavan M, Rangari G, Misra AK, Innamuri SR et al (2024) Bromocriptine: does this drug of Parkinson’s disease have a role in managing cardiovascular diseases? Annals Med Surg 86(2):926–929
doi: 10.1097/MS9.0000000000001642
Kincl V, Panovský R, Bočková M, Rektor I, Mojica-Pisciotti ML, Máchal J (2024) Parkinson´ s disease cardiovascular symptoms: a new complex functional and structural insight. Eur J Neurol 31(2):e16110
pubmed: 37889890
doi: 10.1111/ene.16110
Ukenenye E, Oshiba T, Okoronkwo E, Obomanu E, Asaolu G, Urhi A et al (2023) Quivering hand and heart: Parkinson’s disease is not associated with increased in-hospital mortality in atrial fibrillation hospitalizations: A nationwide analysis. Heliyon. 9(4)
Yang M, Li C, Zhang Y, Ren J (2020) Interrelationship between Alzheimer’s disease and cardiac dysfunction: the brain–heart continuum? Acta Biochim Biophys Sin 52(1):1–8
pubmed: 31897470
doi: 10.1093/abbs/gmz115
Peikert A, Cunningham JW (2023) Amyloid-β and the risk of Heart failure: cause or only Association? American College of Cardiology Foundation Washington DC, pp 103–105
Li J, Wu Y, Zhang D, Nie J (2020) Associations between heart failure and risk of dementia: a PRISMA-compliant meta-analysis. Medicine 99(5):e18492
pubmed: 32000359
pmcid: 7004760
doi: 10.1097/MD.0000000000018492